Associated Papers
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Park JJ et al.
Clinical Genitourinary Cancer, 2026
Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.
Chanhih N et al.
International Journal of Molecular Sciences, 2025
Deep Sequencing Reveals Novel Mutations in Androgen Receptor-Related Genes in Prostate Cancer.
Pedroza-Torres A et al.
International Journal of Molecular Sciences, 2025
Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.
Tsukahara S et al.
Cancer Medicine, 2025
Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.
Shah K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Zengin ZB et al.
Prostate Cancer and Prostatic Diseases, 2025
Histopathologic and Molecular Characterization of IDH-Mutant Prostatic Adenocarcinoma.
Samueli B et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.
Knutson TP et al.
Nature Communications, 2024
Comparison of androgen receptor mutation detection between plasma extracellular vesicle DNA and cell-free DNA and its relationship to prostate cancer prognosis.
Ding T et al.
Annals of Medicine, 2024
Structural perspectives on the androgen receptor, the elusive shape-shifter.
Johnson MJ et al.
Steroids, 2024
Genomic Characterization of Preclinical Prostate Cancer Cell Line Models.
Beatson EL et al.
International Journal of Molecular Sciences, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.
Anselmino N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones.
Hasan AMM et al.
Nature Communications, 2023
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.
Dorff T et al.
Research Square, 2023
Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.
Bang S et al.
Cancers, 2023
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.
Snaterse G et al.
Prostate Cancer and Prostatic Diseases, 2023
A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
Doamekpor SK et al.
Acta Crystallographica. Section F, Structural Biology Communications, 2023
A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance.
Alegre-Martí A et al.
Science Advances, 2023
Yeast-based evolutionary modeling of androgen receptor mutations and natural selection.
Zhang H et al.
Plos Genetics, 2022
Androgen receptor mutations for precision medicine in prostate cancer.
Shiota M et al.
Endocrine-related Cancer, 2022
Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A et al.
International Journal of Biological Macromolecules, 2022
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
Kwan EM et al.
The Prostate, 2022
Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1.
Melnyk JE et al.
Oncogene, 2022
Comprehensive Approach to Distinguish Patients with Solid Tumors from Healthy Controls by Combining Androgen Receptor Mutation p.H875Y with Cell-Free DNA Methylation and Circulating miRNAs.
Tomeva E et al.
Cancers, 2022
Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
Lieb V et al.
Cells, 2021
Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies.
Jacob A et al.
Cancers, 2021
Advancing targeted protein degradation for cancer therapy.
Dale B et al.
Nature Reviews. Cancer, 2021
Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients.
Lallous N et al.
Cancers, 2021
Clinical implications of genomic alterations in metastatic prostate cancer.
Sumiyoshi T et al.
Prostate Cancer and Prostatic Diseases, 2021
Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y et al.
Oncogene, 2021
Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer.
Branch JR et al.
Molecular Cancer Therapeutics, 2021
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS et al.
European Urology, 2021
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H et al.
European Urology, 2020
An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
Dawson NA et al.
Molecular Cancer Therapeutics, 2020
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M et al.
Ebiomedicine, 2020
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Ledet EM et al.
The Oncologist, 2020
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.
Ritch E et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.
Testa U et al.
Medicines (basel, Switzerland), 2019
Detecting predictive androgen receptor modifications in circulating prostate cancer cells.
Steinestel J et al.
Oncotarget, 2019
Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA).
Patsch K et al.
Bmc Research Notes, 2019
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
De Laere B et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T et al.
Scientific Reports, 2019
Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.
Torquato S et al.
Jco Precision Oncology, 2019